

i.e. impaired insulin sensitivity) was associated significantly with the increased risk of HCC recurrence (OR = 7.97, 95% CI = 1.32–152,  $P = 0.0213$ ).

## DISCUSSION

SEVERAL EPIDEMIOLOGICAL STUDIES have revealed the association of DM with cancer incidence and cancer mortality for various organs such as the liver, biliary tract, pancreas, endometrium, kidney, colon, bladder and breast.<sup>7,18–21</sup> The mechanism by which insulin acts as a carcinogenic factor is currently a focus of interests. First, insulin functions as a growth factor by phosphorylating insulin receptor substrate 1 and activating the downstream mitogen-activated protein kinase cascade, which affects cellular proliferation.<sup>22,23</sup> Second, hyperinsulinemia increases peripheral lipolysis and hepatic accumulation of free fatty acids, and the excess  $\beta$ -oxidation in mitochondria and microsome leads to the production of reactive oxygen species<sup>24,25</sup> that play a significant role in carcinogenesis.<sup>26,27</sup> Adipocyte-secreted cytokines (adipokines) such as tumor necrosis factor- $\alpha$  and interleukin-6 also play a significant role in both insulin resistance and carcinogenesis.<sup>28,29</sup> Thus, these factors could cooperatively induce the insulin resistance and carcinogenesis.

We demonstrated in the present study that a higher HOMA-IR level increases the risk of early recurrence after initial curative RFA of stage I HCC in HCV-positive patients. This finding basically agrees with previous studies<sup>7,8,18</sup> that suggested an association between insulin resistance and carcinogenesis as described above, but HbA<sub>1c</sub> level did not predict recurrence (Table 2). This might be explained by the clinical relevance that HbA<sub>1c</sub> level in patients with liver cirrhosis is often underestimated because of anemia. Therefore, the results of the present study suggest that the role of hyperinsulinemia is more important than that of hyperglycemia as reflected by HbA<sub>1c</sub> in the recurrence of HCC. We therefore should pay attention to levels not only of glucose and HbA<sub>1c</sub>, but also of insulin when we follow patients who are at risk for HCC.

Interventional modalities to improve insulin-resistance could be a key to prevent the primary or recurrent HCC in patients complicated with such metabolic disorders. For instance, metformin and thiazolidine derivatives could be potential candidates for this purpose.<sup>30,31</sup> Oral branched-chain amino acid (BCAA) granules might be a candidate for preventing HCC recurrence in DM cases because, in addition to improv-

ing hypoalbuminemia,<sup>32,33</sup> this agent improves insulin resistance without stimulating insulin secretion.<sup>34</sup> Improvements of insulin resistance and glucose tolerance by BCAA have been reported in clinical trials.<sup>35,36</sup> Furthermore, Muto *et al.*<sup>37</sup> described that oral supplementation with BCAA granules inhibited liver carcinogenesis in HCV-positive liver cirrhosis with DM and obesity. Such effect of BCAA is also supported in experimental models.<sup>38,39</sup> These reports,<sup>32–39</sup> together with our present findings (Table 2 and Fig. 1b), suggest that insulin resistance is a significant risk factor for early recurrence of HCC and thus might be a critical target to prevent the recurrence and development of second primary HCC.

A limitation of this study is that the therapeutic effect of the primary HCC was judged as curative by imaging diagnosis but not by surgical pathology. Although the recurrent HCC developed apart from the primary tumor, we could not totally differentiate the recurrent lesion and a second primary HCC. A higher recurrence rate in this study (Fig. 1a) might be explained by this fact. Advanced medical imagings such as positron emission tomography would help solving such limitations in future study of this kind. Furthermore, the basic question, if *de novo*, namely, the first or second primary liver carcinogenesis is regulated by insulin resistance, should be addressed by recruiting HCC-free cirrhotics. However, such study requires a larger sample size and a longer observation period. Instead, we focused on the recurrent HCC, including possible second primary tumors, which develop at a 2–3-fold higher incidence than the first primary one.

Other study limitations are the short observation period, the small number of recruited patients and also the small number of detected events. Such a sample size essentially raises the possibility of  $\beta$ -error, including the absence of the statistical power of AFP and PIVKA-II for predicting the recurrence (Table 2). Previous reports agree that these tumor markers are risk factors of HCC recurrence,<sup>2,6</sup> although some criticisms remain.<sup>4,5</sup> In addition, we should state that the small number of events particularly restricts the reliability of multivariate analysis, while the calculation itself was possible in our study.

In conclusion, we presented for the first time that insulin resistance is significantly associated with the early recurrence of stage I HCC after curative RFA in HCV-positive patients. Increased HOMA-IR, which sensitively reflects insulin resistance, might be a useful biomarker for prediction of high-risk patients who cause early recurrence of HCC.

## ACKNOWLEDGMENTS

THIS WORK WAS supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture (no. 17015016 to H. M.) and from the Ministry of Health, Labor and Welfare of Japan (to H. M.).

## REFERENCES

- Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. *World J Gastroenterol* 2008; 14: 4300–8.
- Koike Y, Shiratori Y, Sato S *et al.* Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus—an analysis of 236 consecutive patients with a single lesion. *Hepatology* 2000; 32: 1216–23.
- Ikeda K, Saitoh S, Tsubota A *et al.* Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. *Cancer* 1993; 71: 19–25.
- Adachi E, Maeda T, Matsumata T *et al.* Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. *Gastroenterology* 1995; 108: 768–75.
- Nagashima I, Hamada C, Naruse K *et al.* Surgical resection for small hepatocellular carcinoma. *Surgery* 1996; 119: 40–5.
- Ishii H, Okada S, Nose H *et al.* Predictive factors for recurrence after percutaneous ethanol injection for solitary hepatocellular carcinoma. *Hepatogastroenterology* 1996; 43: 938–43.
- Wideroff L, Gridley G, Møllekjær L *et al.* Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. *J Natl Cancer Inst* 1997; 89: 1360–5.
- El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* 2004; 126: 460–8.
- Kingston ME, Ali MA, Atiyeh M, Donnelly RJ. Diabetes mellitus in chronic active hepatitis and cirrhosis. *Gastroenterology* 1984; 87: 688–94.
- Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. *J Hepatol* 1994; 21: 1135–9.
- Mehta SH, Brancati FL, Strathdee SA *et al.* Hepatitis C virus infection and incident type 2 diabetes. *Hepatology* 2003; 38: 50–6.
- Marchesini G, Brizi M, Morselli-Labate AM *et al.* Association of nonalcoholic fatty liver disease with insulin resistance. *Am J Med* 1999; 107: 450–5.
- Shintani Y, Fujie H, Miyoshi H *et al.* Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 2004; 126: 840–8.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412–19.
- Wallace TM, Matthews DR. The assessment of insulin resistance in man. *Diabet Med* 2002; 19: 527–34.
- International Union Against Cancer (UICC). Digestive system tumors, liver. In: Sobin LH, Wittekind CH, eds. *TMN Classification of Malignant Tumours*, 5th edn. New York: Wiley-Liss, 1997; 74–7.
- Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. *Diabetes* 2005; 54: 1914–25.
- Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. *Am J Epidemiol* 2004; 159: 1160–7.
- Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F. Markers of insulin resistance and colorectal cancer mortality. *Cancer Epidemiol Biomarkers Prev* 2001; 10: 937–41.
- Silverman DT, Schiffman M, Everhart J *et al.* Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. *Br J Cancer* 1999; 80: 1830–7.
- Lindblad P, Chow WH, Chan J *et al.* The role of diabetes mellitus in the aetiology of renal cell cancer. *Diabetologia* 1999; 42: 107–12.
- Rose DW, Saltiel AR, Majumdar M, Decker SJ, Olefsky JM. Insulin receptor substrate 1 is required for insulin-mediated mitogenic signal transduction. *Proc Natl Acad Sci USA* 1994; 91: 797–801.
- Skolnik EY, Batzer A, Li N *et al.* The function of GRB2 in linking the insulin receptor to Ras signaling pathways. *Science* 1993; 260: 1953–5.
- Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. *Semin Liver Dis* 2001; 21: 57–69.
- Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. *Hepatology* 1998; 27: 128–33.
- Cerutti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. *Cancer Cells* 1991; 3: 1–7.
- Dreher D, Junod AF. Role of oxygen free radicals in cancer development. *Eur J Cancer* 1996; 32A: 30–8.
- Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. *Aliment Pharmacol Ther* 2005; 22 (Suppl 2): 3–10.
- Scott KA, Arnott CH, Robinson SC *et al.* TNF-alpha regulates epithelial expression of MMP-9 and integrin alpha6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? *Oncogene* 2004; 23: 6954–66.
- Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *BMJ* 2005; 330: 1304–5.

- 31 Yu J, Qiao L, Zimmermann L *et al.* Troglitazone inhibits tumor growth in hepatocellular carcinoma *in vitro* and *in vivo*. *Hepatology* 2006; 43: 134–43.
- 32 Marchesini G, Bianchi G, Merli M *et al.* Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. *Gastroenterology* 2003; 124: 1792–801.
- 33 Muto Y, Sato S, Watanabe A *et al.* Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. *Clin Gastroenterol Hepatol* 2005; 3: 705–13.
- 34 Nishitani S, Takehana K, Fujitani S, Sonaka I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. *Am J Physiol Gastrointest Liver Physiol* 2005; 288: G1292–300.
- 35 Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. *Int J Mol Med* 2008; 22: 105–12.
- 36 Urata Y, Okita K, Korenaga K, Uchida K, Yamasaki T, Sakaida I. The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. *Hepatol Res* 2007; 37: 510–16.
- 37 Muto Y, Sato S, Watanabe A *et al.* Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. *Hepatol Res* 2006; 35: 204–14.
- 38 Yoshiji H, Noguchi R, Kitade M *et al.* Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. *J Gastroenterol* 2009; 44: 483–91.
- 39 Shimizu M, Shirakami Y, Iwasa J *et al.* Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. *Clin Cancer Res* 2009; 15: 3068–75.

# Momordica charantia leaf extract suppresses rat prostate cancer progression *in vitro* and *in vivo*

Pornsiri Pitchakarn,<sup>1,2</sup> Kumiko Ogawa,<sup>1,3</sup> Shugo Suzuki,<sup>1</sup> Satoru Takahashi,<sup>1</sup> Makoto Asamoto,<sup>1</sup> Teera Chewonarin,<sup>2</sup> Pornngarm Limtrakul<sup>2</sup> and Tomoyuki Shirai<sup>1,4</sup>

<sup>1</sup>Department of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan; <sup>2</sup>Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; <sup>3</sup>Division of Pathology, National Institute of Health Sciences, Tokyo, Japan

(Received March 3, 2010/Revised May 30, 2010/Accepted June 18, 2010/Accepted manuscript online July 6, 2010/Article first published online July 29, 2010)

Cancer metastasis is a major cause of death in cancer patients, with invasion as a first step greatly contributing to the failure of clinical treatments. Any compounds with an inhibitory influence on this process are therefore of prime interest. *Momordica charantia* (bitter melon) is widely consumed as a vegetable and especially as a folk medicine in Asia. Here, we investigated the anti-invasive effects of bitter melon leaf extract (BMLE) on a rat prostate cancer cell line (PLS10) *in vitro* and *in vivo*. The results indicated that non-toxic concentrations of BMLE significantly inhibited the migration and invasion of cells *in vitro*. The results of zymography showed that BMLE inhibited the secretion of MMP-2, MMP-9 and urokinase plasminogen activator (uPA) from PLS10. Real-time RT-PCR revealed that BMLE not only significantly decreased gene expression of MMP-2 and MMP-9, but also markedly increased the mRNA level of TIMP-2, known to have inhibitory effects on the activity of MMP-2. An EnzChek gelatinase/collagenase assay showed that collagenase type IV activity was partially inhibited by BMLE. In the *in vivo* study, intravenous inoculation of PLS10 to nude mice resulted in a 100% survival rate in the mice given a BMLE-diet as compared with 80% in the controls. The incidence of lung metastasis did not show any difference, but the percentage lung area occupied by metastatic lesions was slightly decreased in the 0.1% BMLE treatment group and significantly decreased with 1% BMLE treatment as compared with the control. Thus, the results indicate for the first time an anti-metastatic effect of BMLE both *in vitro* and *in vivo*. (*Cancer Sci* 2010; 101: 2234–2240)

Prostate cancer is the most common male malignant tumor in Western countries.<sup>(1)</sup> Androgen ablation therapy is widely used for the initial stage of this disease and may produce favorable outcome, but most patients eventually develop ablation-resistant prostate cancers with metastatic foci. Currently, there is no treatment that is able to cure progressive hormone-refractory metastatic prostate cancer.

Metastasis is a multi-step process, which involves a series of processes including cellular adhesion and invasion through the basement membrane, transfer via the circulation system, extravasation, and proliferation at a distant site.<sup>(2,3)</sup> Multiple organ failure caused by multiple metastasis is a major cause of death in cancer patients. Therefore, prevention of tumor metastasis is one primary goal. However, cytotoxic agents have generally been applied for tumor metastasis therapy, with serious side-effects that can diminish the quality of life of cancer patients.<sup>(4)</sup> Recently, many efforts have therefore been made to search for non- or low-cytotoxic agents that can reduce the spread of malignant tumors. One focus is on cell invasion using substances in medicinal plants.<sup>(5,6)</sup>

*Momordica charantia*, or bitter melon, has long been frequently used in various Asian traditional medicine systems and commonly consumed as a vegetable.<sup>(7,8)</sup> Extracts have been

reported to possess anti-cancer activity against lymphoid leukemia, lymphoma, choriocarcinoma, melanoma, breast cancer, skin tumor, prostatic cancer, squamous carcinoma of the tongue and larynx, human bladder carcinomas and Hodgkin's disease.<sup>(9–14)</sup> In addition, antioxidant,<sup>(15)</sup> antiviral (human immunodeficiency virus [HIV] inhibitor),<sup>(16)</sup> antidiabetic<sup>(17)</sup> and immunomodulating properties<sup>(18)</sup> have been described. A previous study demonstrated that Thai *Momordica charantia* induced Phase II enzymes and repressed monooxygenase, whereas a Chinese variety only affected monooxygenase.<sup>(19)</sup> Our previous study showed that the bitter melon leaf extract (BMLE) in Thailand reversed the multidrug resistant (MDR) phenotype in cervical carcinoma, KB-V1 cells and increased their sensitivity to a chemotherapeutic agent, vinblastine.<sup>(20)</sup> However, evidence that BMLE has effects on prostate cancer cell invasion has hitherto been lacking. In this study we therefore examined the inhibitory effects of BMLE against progression of a prostate cancer cell line both *in vitro* and *in vivo*. The androgen-independent, androgen receptor-negative rat prostate cancer cell line (PLS10), which was established in our laboratory from a 3,2'-dimethyl-4-aminobiphenyl plus testosterone-induced carcinoma in the dorsolateral prostate of a male F344 rat,<sup>(21)</sup> was used in this study.

## Materials and Methods

**Plant material and extraction.** Bitter melon leaves were harvested from the plantation of Lampang Herb Conservation Assembly in Lampang, Thailand and the voucher specimen number was certified by the herbarium at the Flora of Thailand Faculty of Pharmacy, Chiang Mai University.

Fresh leaves of bitter melon were dried at 30–45°C, ground and a sample (1 kg) was extracted exhaustively with 4 L of 80% ethanol by maceration at 37°C for 16 h. The mixture was filtered and re-extracted with 4 L of ethanol. The combined filtrate was bleached with 160 g of active charcoal, filtered and concentrated by rotary evaporation to 120 mL before filtering to remove precipitates. The filtrate was again rotary evaporated and lyophilized then kept at –20°C protected from light. For the *in vitro* study, BMLE was dissolved in a final DMSO concentration adjusted to 0.1% (v/v) in the culture medium.

**Cell culture.** The PLS10 cell line was cultured in Roswell Park Memorial Institute-1640 Medium (RPMI 1640, Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Life Technologies Japan Ltd, Japan), 50 U/mL penicillin and 50 µg/mL streptomycin, in a humidified incubator with an atmosphere comprising 95% air and 5% CO<sub>2</sub> at 37°C. When the cells reached 70–80% confluence, they were harvested and plated either for subsequent passage or for treatment.

**Animals.** The animal experiment was performed under protocols approved by the Institutional Animal Care and Use

<sup>4</sup>To whom correspondence should be addressed.  
E-mail: tshirai@med.nagoya-cu.ac.jp

Committee of Nagoya City University Graduate School of Medical Sciences. Six-week-old male athymic nude mice (KSN strain) were purchased from Nihon SLC (Hamamatsu, Japan) and housed in plastic cages with hardwood chip bedding in an air-conditioned room at  $23 \pm 2^\circ\text{C}$  and  $55 \pm 5\%$  humidity with a 12 h light/dark cycle. Oriental MF powder diet (Oriental MF, Oriental Yeast Co., Tokyo, Japan) and distilled water were available *ad libitum*.

**Cytotoxicity and growth inhibition assay.** PLS10 cells were plated at  $2.0 \times 10^3$  cells per well in 96-well plates. Twenty-four hours after plating, various concentrations of BMLE were added. The cells were then incubated for 24 and 48 h at  $37^\circ\text{C}$ , and cell growth was assessed by WST-1 colorimetric assay (Roche Diagnostics, Mannheim, Germany).<sup>(22)</sup> In each experiment, determinations were carried out in triplicate.

**Invasion and migration assays.** For the invasion and migration assays, the cells were seeded in BD Biocoat Matrigel invasion chambers and the BD Falcon 24-multiwell insert system (BD Biosciences, Qume Drive San Jose, CA, USA), respectively, with BMLE (0, 25 and 50  $\mu\text{g}/\text{mL}$ ) for 24 and 48 h, with 5% fetal bovine serum used as a chemoattractant. Invading or migrating cells were fixed with 100% ethanol for 5 min, then stained with 0.5% crystal violet in 20% methanol for 30 min. The percentage of areas occupied with cells were then determined with IMAGEJ 1.410 (National Institute of Mental Health, Bethesda, MD, USA).

**Zymography.** PLS10 cells were maintained in serum-free DMEM for 24 h then treated with various concentrations (0, 25 and 50  $\mu\text{g}/\text{mL}$ ) of BMLE. Matrix metalloproteinase (MMP)-2 and MMP-9 secretion into the conditioned medium was detected by gelatin zymography as previously described.<sup>(23)</sup> Samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a 10% acrylamide gel containing 0.1 mg/mL of gelatin (Bio-Rad Laboratories, Hercules, CA, USA) under non-reducing conditions. After electrophoresis, SDS in the gel was washed twice with 2.5% Triton-X 100 then incubated at  $37^\circ\text{C}$  in the incubating buffer (50 mM Tris-HCl, 200 mM NaCl, and 10 mM  $\text{CaCl}_2$ , pH 7.4) for 24 h. After incubation, the gel was stained with 0.1% Coomassie brilliant blue R250 (Bio-Rad Laboratories) in 50% methanol/10% acetic acid, and destained with 10% acetic acid/50% methanol. Bands of gelatinolytic activity were analyzed using IMAGEJ 1.410.

Urokinase plasminogen activator (uPA) secretion from the PLS10 cells into the culture medium was also examined by casein-plasminogen zymography.<sup>(24)</sup> The culture supernatant was separated by electrophoresis in 10% polyacrylamide gel (PAGE) in the presence of SDS, which was copolymerized with 1 mg/mL  $\beta$ -casein and 10  $\mu\text{g}/\text{mL}$  human plasminogen (Sigma-Aldrich, Co., St Louis, MD, USA) under non-reducing conditions. After electrophoresis, the gel was washed twice with 2.5% Triton X 100 and incubated in incubating buffer for 18 h at  $37^\circ\text{C}$ , then stained and destained as described above.

**Collagenase IV assays.** An EnzChek Gelatinase/Collagenase Assay kit (Life Technologies Japan Ltd, Tokyo, Japan) was used for measuring gelatinase or collagenase activity. The substrate, DQ fluorescein-conjugate gelatin, was incubated with collagenase type IV from *Clostridium histolyticum* with BMLE (0, 25, 50 and 100  $\mu\text{g}/\text{mL}$ ) for 1.5 h and fluorescence signal representing proteolytic activity was measured using a fluorescence microplate reader (480/530 nm).

**Real-Time RT-PCR.** After treatment with various concentrations (0, 25 and 50  $\mu\text{g}/\text{mL}$ ) of BMLE, total RNA from cell lysates was extracted with an RNeasy Mini kit (Qiagen sciences, Germantown, MD, USA) and then 1  $\mu\text{g}$  of RNA was converted to cDNA with avian myoblastosis virus reverse transcriptase (Takara, Shiga, Japan). cDNA samples were subjected to quantitative PCR using SYBR Premix ExTaq (Takara) in a Light

Cycler apparatus (Roche Diagnostics). MMP-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-2 mRNA levels were quantified using the following primers: MMP-2 forward, 5'-ACCAGAACCACCATCGAGACC-3' and reverse 5'-GAGTC-CACAGCTCATCGTCA-3'; MMP-9 forward, 5'-GTAACCCCTGGTACCAGGACTT-3', and reverse 5'-TTCACCCGGTTGTG-GAAACT-3'; TIMP-2 forward, 5'-GCATCACCCAGAAGAA-GAGC-3' and reverse 5'-TCCAGGAAGGGATGTCAAAG-3'. The house-keeping gene, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as an internal control to normalize reactions.

**Quantitative immunoenzymatic assay (ELISA) for transforming growth factor- $\beta$ 1.** PLS10 cells were maintained in serum-free DMEM and treated with various concentrations (0, 25 and 50  $\mu\text{g}/\text{mL}$ ) of BMLE for 24 h. The levels of total and activated transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) in the conditioned medium were determined by Mouse/Rat/Porcine/Canine TGF- $\beta$ 1 Immunoassay (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions.

**Metastasis assays in nude mice.** After 1 week of acclimation, mice were divided into three groups of 10 mice each and given BMLE (0, 0.1 and 1% w/w) for 3 weeks and a basal diet afterwards. One week after the start of the BMLE treatment, PLS10 cells ( $1 \times 10^6$ /animal) were injected into the tail vein. Mice were killed at experimental week 4.

At death, visible tumors and the heart, liver, lung, kidneys, spleen were removed and fixed in 10% formalin. At least one section of each tissue and the largest section from each lobe of the lung were processed for hematoxylin and eosin (HE) and Ki-67 staining. For quantitative analysis of lung metastases, numbers and areas of metastatic foci per total area of section were determined using an Image Processor for Analytical Pathology (IPAP-WIN; Sumika Technos Co., Osaka, Japan). For this experiment, immunostaining of Ki-67 was also used as a subsidiary method.


**Immunohistochemistry.** For Ki-67 immunostaining, paraffin-embedded specimens were sectioned (5  $\mu\text{m}$ ) and stained with Ki-67 antibody (DAKO, Denmark A/S, Glostrup, Denmark) and sequentially with anti-rabbit secondary antibody and avidin-biotin complex (Vectastain Elite ABC kit; Vector Laboratory, Burlingame, CA, USA), then binding sites were visualized with diaminobenzidine. The sections were then counterstained lightly with hematoxylin for microscopic examination.

**Statistical analysis.** All *in vitro* experiments were performed at least in triplicate to confirm reproducibility. Statistical analyses were performed with mean  $\pm$  SD values using one-way ANOVA, the Bonferroni correction and the Student's *t*-test. Statistical significance was concluded with  $*P < 0.05$  or  $**P < 0.01$ .

## Results

**Effects of BMLE on the cytotoxicity and growth inhibition of PLS10 cells.** WST-1 assay (Fig. 1a) showed that BMLE treatment reduced cell growth of PLS10 cells concentration-dependently for 24 and 48 h. At concentrations higher than 100  $\mu\text{g}/\text{mL}$ , BMLE treatment significantly inhibited growth, and inhibitory concentration (IC) 50 of BMLE was in the range of 150–200  $\mu\text{g}/\text{mL}$ . Treatment with 75  $\mu\text{g}/\text{mL}$  BMLE for 24 or 48 h was not cytotoxic to the PLS10 cells. Thus, a range of non-toxic concentrations (25 or 50  $\mu\text{g}/\text{mL}$ ) was applied for all subsequent experiments.

**BMLE inhibition of invasion and migration of PLS10 cells.** The data and representative images of invasion and migration studies are presented in Figure 1b,c, respectively. Cell invasion of PLS10 was inhibited by up to 49% and 59% with 25 and 50  $\mu\text{g}/\text{mL}$  of BMLE, respectively. The same concentrations of BMLE also inhibited cell migration, by about 38% and 64%, respectively.



**Fig. 1.** Bitter melon leaf extract (BMLE) inhibited invasion and migration of PLS10 cells. The cells were incubated with BMLE for 24 and 48 h and then cytotoxicity was assessed by WST-1 assay (a). The cells were treated with 0, 25 and 50 µg/mL BMLE for invasion assays (48 h) and migration assays (24 h) using transwell cell culture chambers, with 5% fetal bovine serum as a chemoattractant. Cells were photographed under phase-contrast microscopy (c) and quantified (b). The results are expressed as percentages of untreated control values. Data are mean ± SD values from three independent experiments. \* $P < 0.05$  and \*\* $P < 0.01$ .

**Reduction of MMP-2, MMP-9 and uPA secretion from PLS10 cells by BMLE.** Zymography showed that secretion of MMP-2, MMP-9 and uPA was reduced with BMLE treatment in a concentration-dependent manner. The inhibition of MMP-2 (pro- and active-form) secretion was about 22% and 46% at 24 h, and 19% and 33% at 48 h, with 25 and 50 µg/mL of BMLE, respectively (Fig. 2a,b). As shown in Figure 2c,d, BMLE also inhibited the secretion of MMP-9 (active-form), by approximately 11% and 27% at 24 h, and 17% and 29% at 48 h at the concentrations of 25 and 50 µg/mL, respectively. Moreover, secretion of uPA was significantly reduced by 25 and 50 µg/mL of BMLE, by approximately 26% and 28%, respectively, for the pro-form and 45% and 61% for the active-form (Fig. 2e,f). Collectively, these results indicated secretion of MMP-2, MMP-9 and uPA to be significantly inhibited by BMLE.

**BMLE inhibition of collagenase type IV activity.** Because of reduction of MMP protein expression by the BMLE treatment, effects on MMP activity were investigated with a Collagenase Assay kit. It was found that proteolytic activity of collagenase type IV was slightly inhibited by 9%, 15% and 17% with 25, 50 and 100 µg/mL of BMLE, respectively (Fig. 2g).

**Effects of BMLE on MMP-2, MMP-9 and TIMP-2 mRNA expression.** Quantitative real-time RT-PCR results showed that BMLE treatment significantly decreased gene expression of MMP-2, by approximately 31% and 75% at 24 h, and 26% and 62% at 48 h, with 25 and 50 µg/mL of BMLE, respectively (Fig. 3a). Similarly, the expression of MMP-9 was inhibited by approximately 46% and 66% at 24 h, and 18% and 83% at 48 h (Fig. 3b). TIMP-2, which has been known to have an inhibitory effect on the activity of MMP-2 mRNA level, was up-regulated


to 152% and 231% at 24 h, and 128% and 222% at 48 h (Fig. 3c).

**Effects of BMLE on TGF-β1 secretion.** Quantitative ELISA showed that TGF-β1 secretion from PLS10 cells was not altered by 25 and 50 µg/mL of BMLE. TGF-β1 secretion by PLS10 treated with 0 (control), 25 and 50 µg/mL of BMLE was  $539 \pm 87$ ,  $571 \pm 108$  and  $540 \pm 109$  (pg/mL), respectively, for total TGF-β1, and  $32 \pm 14$ ,  $30 \pm 14$  and  $29 \pm 11$  (pg/mL) for activated TGF-β1.

**Effects of BMLE on lung metastasis of PLS10 cells in nude mice.** Four weeks after BMLE treatment, the percentage survival of nude mice in the BMLE-treated groups (100%) was higher than in the controls (80%; Fig. 4a). Administration of BMLE caused no depression in bodyweight (Table 1). All mice developed metastatic nodules in their lungs, which are represented in Figure 4b. Two mice in each group also developed metastasis in the heart and the incidences of metastasis among groups did not differ. The lung weights and the number of tumor in the lung were slightly decreased in the BMLE-treated group, but without significance (Table 1). The calculated tumor metastatic area in the lung was slightly decreased in the 0.1% BMLE group and significantly decreased in the 1% BMLE group, by 35% and 48% relative to the control group, respectively (Table 1). The Ki-67 labeling index was not different among groups (Table 1). There were no metastatic foci apparent in the liver, kidneys and spleen.

## Discussion

The present results provided clear evidence that an extract of bitter melon leaves can exert inhibitory potential against




**Fig. 2.** Bitter melon leaf extract (BMLE) reduction of the secretion of MMP-2, MMP-9 and urokinase plasminogen activator (uPA) from PLS10 and collagenase type IV activity. Cells were treated with 0, 25 and 50 µg/mL BMLE for the indicated time under serum-free conditions. Gelatin zymography was performed for detection of MMP-2 (a) and MMP-9 (c). The uPA secretion was analyzed by casein-plasminogen zymography (e). Levels of MMP-2 (pro- and active-form), MMP-9 (active-form), and uPA (pro- and active-form) were quantified (b,d,f). Gelatinase or collagenase activity was assessed (g). The results are percentages of the control values. Data are mean ± SD values from three independent experiments. \* $P < 0.05$  and \*\* $P < 0.01$ .

metastatic properties of PLS10 cells in both *in vitro* and *in vivo* experiments. *Momordica charantia*, or bitter melon, has been shown to be safe without any signs of nephrotoxicity and hepatotoxicity and any adverse influence on food intake, growth organ weights and hematological parameters in experimental animals when ingested at low doses for up to 2 months.<sup>(25,26)</sup> Although animal studies showed toxicity of bitter melon when extracts were injected intravenously or intraperitoneally, with extracts from fruit and seed having relatively higher toxicity than the leaf or aerial parts of the plant,<sup>(14,19,27)</sup> our results pointed to beneficial effects at non-toxic levels. The BMLE might thus afford an advantageous anti-cancer progression agent especially for tumor metastasis therapy.

An important aspect of high incidence of morbidity and mortality in prostate cancer is tumor invasiveness and metastasis.



Metastasis is accompanied by various physiological alterations involved in extracellular matrix (ECM) degradation, which allows cancer cells to invade the blood or the lymphatic system and spread to another tissue or organ. In this study, non-cytotoxic BMLE treatment dramatically reduced migration and invasion properties of androgen-independent rat prostate cancer cells. It has been postulated that cell-ECM interactions are essential for invasion, migration and metastasis of tumors.<sup>(28,29)</sup> MMP play important roles in ECM degradation for tumor growth, invasion and angiogenesis.<sup>(30)</sup> Among MMP, MMP-2 and MMP-9 are reported to be the most important for basement membrane type IV collagen degradation,<sup>(31,32)</sup> and their expression correlates with an aggressive, invasive or metastatic tumor phenotype.<sup>(33-35)</sup> Therefore, MMP-2 and MMP-9 are candidate molecules as targets for therapeutic anticancer drugs. We



**Fig. 3.** Effects of bitter melon leaf extract (BMLE) on MMP-2, MMP-9 and TIMP-2 gene expression. PLS10 cells were treated with 0, 25 and 50 µg/mL BMLE for 24 and 48 h and then total RNA samples were extracted and subjected to a real-time PCR, with GADPH used as an internal control. The mRNA expression of MMP-2 (a), MMP-9 (b) and TIMP-2 (c) is presented as percentages of untreated control values. Data are mean  $\pm$  SD values from three independent experiments. \* $P < 0.05$  and \*\* $P < 0.01$ .

showed here that BMLE treatment reduced not only secretion but also expression of MMP-2 and MMP-9 in the PLS10 cell line. Additionally, uPA, which is an upstream enzyme of MMP also implicated in tumor cell invasion, survival and metastasis,<sup>(36,37)</sup> was similarly reduced by the BMLE treatment. Since TIMP have the ability to form tight 1:1 complexes with the active MMP enzymes, changes in TIMP levels directly affect MMP activity.<sup>(38,39)</sup> Increase of TIMP-2 protein may inhibit tumor cell invasion,<sup>(40,41)</sup> and in this study the BMLE treatment induced the expression of TIMP-2. In addition, BMLE slightly reduced proteolytic activity of collagenase type IV. Therefore, BMLE might mainly reduce activity of MMP by suppression of uPA and induction of TIMP-2, and also partially inhibit MMP activity directly.

TGF- $\beta$  is a member of a superfamily of multifunctional cytokines that has been reported to be associated with enhanced angiogenesis and metastasis in prostate cancer.<sup>(42,43)</sup> Down-regulation of TGF- $\beta$ 1 reduces tumorigenicity of prostate cancer cells.<sup>(44)</sup> It has been reported that bitter melon extract induced the secretion of TGF- $\beta$  in colon cancer cell line, Caco-2 cell,<sup>(45)</sup> but induction of TGF- $\beta$  by extract has been not reported in prostate cancer. The present study showed that the secretion of



**Fig. 4.** Bitter melon leaf extract (BMLE) suppression of lung metastasis in an intravenously inoculated mouse prostate tumor model. For the metastasis assay in nude mice, animals were given BMLE (0, 0.1 and 1% w/w) in their diet during the 1–3 week experimental period, 1 week after PLS10 cells ( $1 \times 10^6$ /animal) were injected into the tail vein. Mice were killed at week 4. The percentage survival of nude mice represented as a Kaplan-Meier survival curve (a). Representative hematoxylin and eosin staining of lung metastases (b).

TGF- $\beta$ 1 was not effected by BMLE, indicating that the BMLE did not modulate the prostate cancer cell migration and invasion via TGF- $\beta$ 1 signaling. In addition, a previous study showed that promoter regions of TGF- $\beta$  receptor type 2 gene were methylated and the expression was downregulated in the PLS10 cell line.<sup>(46)</sup> Hence, TGF- $\beta$  signaling might not be the critical mechanisms for the cancer cell metastasis.

*In vivo* study further showed that dietary BMLE treatment tended to reduce the lung weight and number of lung metastatic tumors. Treatment of BMLE significantly reduced the percentage of tumor area in the lungs in a dose-response manner, at



**Table 1. Effect of bitter melon leaf extract (BMLE) on bodyweight and lung metastasis of PLS-10 cells in nude mice**

Group	Bodyweight (g)	Lung weight (g)	Number of tumors (No./mm <sup>2</sup> )	Percentage of tumor area (%)	Ki-67 LI in tumors (%)
Control	24.45 ± 2.7	0.5 ± 0.23	2.18 ± 0.43	36.1 ± 11.1	89.4 ± 3.1
0.1% BMLE	25.57 ± 2.9	0.5 ± 0.18	1.66 ± 0.79	23.3 ± 18.0	91.2 ± 1.4
1% BMLE	24.66 ± 2.3	0.4 ± 0.25	1.67 ± 0.72	18.6 ± 9.6*	89.4 ± 3.1

\**P* < 0.05 compared with the control group. Values are expressed as the mean ± SD. LI, labeling index.

least in terms of the lesion size. In the histopathology, excessive numbers of metastatic tumors developed and coalesced in the lungs; therefore, a significant effect was not evident on incidence or multiplicity. Additionally, no difference in cell proliferation was evident among the groups. Further studies might be needed to characterize the active constituents of BMLE and confirm BMLE effects on metastasis *in vivo*.

Recently, several triterpenoids from various plants have been reported to feature anti-proliferative<sup>(47–49)</sup> and anti-invasive<sup>(50,51)</sup> bioactive components. More than 50 triterpenoids have been isolated from bitter melon, but their biological activities are yet to be explored in detail. However, it was shown that Cucurbitacin B (cucB), a triterpenoid from Cucurbitaceae vegetables also found in bitter melon seeds, caused cell-cycle arrest and apoptosis induction in human colon adenocarcinoma cancer cells.<sup>(49)</sup> Moreover, two flavonoids and four phenolic acids, including rutin, naringin, gentistic acid, benzoic acid, *o*-coumaric acid and *t*-cinamic acid, are present in bitter melon leaves.<sup>(52)</sup> Rutin, a flavonoid glycoside, has been reported to show growth inhibition of leukemia and ovarian carcinomas, with anti-invasive effects on

melanoma.<sup>(52–55)</sup> Triterpenoids and flavonoids included in BMLE might be promising components with critical roles against cancer cell progression, but active compound(s) remain to be identified.

Taken together, our results provide the first evidence that BMLE exerts inhibitory effects on the progression of rat prostate cancer cells *in vitro* and *in vivo*. The exact nature of the active components of bitter melon leaf extracts that exert anti-invasion effects now needs to be explored, along with further elucidation of the underlying molecular mechanisms.

### Acknowledgments

This work was supported by grants from the Royal Golden Jubilee PhD Program of Thailand, the Research Foundation for Oriental Medicine and the Society for Promotion of Pathology of Nagoya, Japan.

### Disclosure Statement

The authors have no conflict of interest.

### References

- Gronberg H. Prostate cancer epidemiology. *Lancet* 2003; **361**: 859–64.
- Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. *Science* 1977; **197**: 893–5.
- Nagase H, Woessner JF Jr. Matrix metalloproteinases. *J Biol Chem* 1999; **274**: 21491–4.
- Braun-Falco M, Holtmann C, Lordick F, Ring J. Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma. *Hautarzt* 2006; **57**: 701–4.
- Yodkeeree S, Garbisa S, Limtrakul P. Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA. *Acta Pharmacol Sin* 2008; **29**: 853–60.
- Lin SS, Lai KC, Hsu SC *et al*. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). *Cancer Lett* 2009; **285**: 127–33.
- Giron LM, Freire V, Alonzo A, Caceres A. Ethnobotanical survey of the medicinal flora used by the Caribs of Guatemala. *J Ethnopharmacol* 1991; **34**: 173–87.
- Lans C, Brown G. Observations on ethnoveterinary medicines in Trinidad and Tobago. *Prev Vet Med* 1998; **35**: 125–42.
- Licastro F, Franceschi C, Barbieri L, Stirpe F. Toxicity of Momordica charantia lectin and inhibitor for human normal and leukaemic lymphocytes. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1980; **33**: 257–65.
- Ng TB, Liu WK, Sze SF, Yeung HW. Action of alpha-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines. *Gen Pharmacol* 1994; **25**: 75–7.
- Battelli MG, Polito L, Bolognesi A, Lafleur L, Fradet Y, Stirpe F. Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. *Int J Cancer* 1996; **65**: 485–90.
- Ganguly C, De S, Das S. Prevention of carcinogen-induced mouse skin papilloma by whole fruit aqueous extract of Momordica charantia. *Eur J Cancer Prev* 2000; **9**: 283–8.
- Sun Y, Huang PL, Li JJ, Huang YQ, Zhang L, Lee-Huang S. Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus. *Biochem Biophys Res Commun* 2001; **287**: 983–94.
- Basch E, Gabardi S, Ulbricht C. Bitter melon (*Momordica charantia*): a review of efficacy and safety. *Am J Health Syst Pharm* 2003; **60**: 356–9.
- Shi H, Hiramatsu M, Komatsu M, Kayama T. Antioxidant property of Fructus Momordicae extract. *Biochem Mol Biol Int* 1996; **40**: 1111–21.
- Lee-Huang S, Huang PL, Chen HC, Bourinbaier A, Huang HI, Kung HF. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. *Gene* 1995; **161**: 151–6.
- Tan MJ, Ye JM, Turner N *et al*. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. *Chem Biol* 2008; **15**: 263–73.
- Cunnick JE, Sakamoto K, Chapes SK, Fortner GW, Takemoto DJ. Induction of tumor cytotoxic immune cells using a protein from the bitter melon (*Momordica charantia*). *Cell Immunol* 1990; **126**: 278–89.
- Kusamran WR, Ratanavila A, Tepsuwan A. Effects of neem flowers, Thai and Chinese bitter gourd fruits and sweet basil leaves on hepatic monooxygenases and glutathione S-transferase activities, and *in vitro* metabolic activation of chemical carcinogens in rats. *Food Chem Toxicol* 1998; **36**: 475–84.
- Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by *Momordica charantia* extract. *Cancer Chemother Pharmacol* 2004; **54**: 525–30.
- Nakanishi H, Takeuchi S, Kato K *et al*. Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2'-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats. *Jpn J Cancer Res* 1996; **87**: 1218–26.
- Hamasaki K, Kogure K, Ohwada K. A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt. *Toxicol* 1996; **34**: 490–5.
- Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. *Circ Res* 1999; **85**: 906–11.
- Law B, Hsiao JK, Bugge TH, Weissleder R, Tung CH. Optical zymography for specific detection of urokinase plasminogen activator activity in biological samples. *Anal Biochem* 2005; **338**: 151–8.
- Platel K, Shurpalekar KS, Srinivasan K. Influence of bitter gourd (*Momordica charantia*) on growth and blood constituents in albino rats. *Nahrung* 1993; **37**: 156–60.
- Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK. Antihyperglycemic effects of three extracts from *Momordica charantia*. *J Ethnopharmacol* 2003; **88**: 107–11.
- Subratty AH, Gurib-Fakim A, Mahomoodally F. Bitter melon: an exotic vegetable with medicinal values. *Nutr Food Sci* 2005; **35**: 143–7.
- Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. *Annu Rev Biochem* 1986; **55**: 1037–57.

- 29 Gilles C, Polette M, Seiki M, Birembaut P, Thompson EW. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. *Lab Invest* 1997; **76**: 651–60.
- 30 Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. *FASEB J* 1999; **13**: 781–92.
- 31 Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. *Carcinogenesis* 1999; **20**: 749–55.
- 32 Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. *Cancer Metastasis Rev* 1990; **9**: 289–303.
- 33 Wang M, Wang T, Liu S, Yoshida D, Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. *Brain Tumor Pathol* 2003; **20**: 65–72.
- 34 Papathoma AS, Zoumpourlis V, Balmain A, Pintzas A. Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis. *Mol Carcinog* 2001; **31**: 74–82.
- 35 Cockett MI, Murphy G, Birch ML *et al*. Matrix metalloproteinases and metastatic cancer. *Biochem Soc Symp* 1998; **63**: 295–313.
- 36 Li Y, Cozzi PJ. Targeting uPA/uPAR in prostate cancer. *Cancer Treat Rev* 2007; **33**: 521–7.
- 37 Pulukuri SM, Gondi CS, Lakka SS *et al*. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. *J Biol Chem* 2005; **280**: 36529–40.
- 38 Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc Res* 2006; **69**: 562–73.
- 39 Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. *Cancer Metastasis Rev* 2006; **25**: 115–36.
- 40 Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. *J Neurosurg* 1995; **83**: 298–307.
- 41 George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. *Gene Ther* 1998; **5**: 1552–60.
- 42 Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. *Clin Cancer Res* 1999; **5**: 711–20.
- 43 Konrad L, Scheiber JA, Schwarz L, Schrader AJ, Hofmann R. TGF-beta1 and TGF-beta2 strongly enhance the secretion of plasminogen activator inhibitor-1 and matrix metalloproteinase-9 of the human prostate cancer cell line PC-3. *Regul Pept* 2009; **155**: 28–32.
- 44 Matthews E, Yang T, Janulis L *et al*. Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells. *Br J Cancer* 2000; **83**: 519–25.
- 45 Manabe M, Takenaka R, Nakasa T, Okinaka O. Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter melon). *Biosci Biotechnol Biochem* 2003; **67**: 2512–7.
- 46 Yamashita S, Takahashi S, McDonnell N *et al*. Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers. *Cancer Res* 2008; **68**: 2112–21.
- 47 Lavhale MS, Kumar S, Mishra SH, Sitasawad SL. A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent. *PLoS ONE* 2009; **4**: 53–65.
- 48 Sun C, Zhang M, Shan X *et al*. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. *J Cancer Res Clin Oncol* 2010; **136**: 603–10.
- 49 Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H, Sakai T. Cucurbitacin B induces G(2) arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. *Mol Nutr Food Res* 2010; **54**: 559–65.
- 50 Yanamandra N, Berhow MA, Konduri S *et al*. Triterpenoids from Glycine max decrease invasiveness and induce caspase-mediated cell death in human SNB19 glioma cells. *Clin Exp Metastasis* 2003; **20**: 375–83.
- 51 Weng CJ, Chau CF, Chen KD, Chen DH, Yen GC. The anti-invasive effect of lucidenic acids isolated from a new Ganoderma lucidum strain. *Mol Nutr Food Res* 2007; **51**: 1472–7.
- 52 Zhang M, Hettiarachchy NS, Horax R, Chen P, Over KF. Effect of maturity stages and drying methods on the retention of selected nutrients and phytochemicals in bitter melon (Momordica charantia) leaf. *J Food Sci* 2009; **74**: C441–8.
- 53 Lin JP, Yang JS, Lu CC *et al*. Rutin inhibits the proliferation of murine leukemia WEHI-3 cells in vivo and promotes immune response in vivo. *Leuk Res* 2009; **33**: 823–8.
- 54 Luo H, Jiang BH, King SM, Chen YC. Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. *Nutr Cancer* 2008; **60**: 800–9.
- 55 Martinez Conesa C, Vicente Ortega V, Yanez Gascon MJ *et al*. Treatment of metastatic melanoma B16F10 by the flavonoids tangeretin, rutin, and diosmin. *J Agric Food Chem* 2005; **53**: 6791–7.

## Original Article

## Hypertension is positively associated with prostate cancer development in the TRAP transgenic rat model

Kentaro Takeshita, Satoru Takahashi, Mingxi Tang,\* Azman Seeni,† Makoto Asamoto and Tomoyuki Shirai

Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

**Epidemiological data on the relationship between hypertension and prostate cancer development are conflicting. To cast light on this question, we performed animal experiments using hybrid rats generated by crossing the spontaneously hypertensive rat (SHR) or its normotensive control Wistar Kyoto (WKY) rat with a transgenic rat for adenocarcinoma of prostate (TRAP) that features development of adenocarcinoma at high incidence by 15 weeks of age. The number of adenocarcinomatous foci in the lateral prostate of hypertensive (TRAP × SHR)F1 rats was demonstrated to be significantly increased compared with those of normotensive (TRAP × WKY)F1 rats. In the ventral prostate, increase of carcinoma foci was also observed but did not reach significance. The number of cancer foci showing microinvasion in (TRAP × SHR)F1 rats was higher than that of (TRAP × WKY)F1 rats, but again without significance, while treatment with prazosin, an anti-hypertensive agent, tended to decrease microinvasive carcinoma foci in both the ventral and lateral prostate. In conclusion, the present study provided additional evidence that high blood pressure is associated with prostate cancer risk.**

**Key words:** hypertension, prazosin, prostate cancer, SHR, TRAP, WKY

Prostate cancer now has the highest incidence of all non-cutaneous neoplasms in men in Western countries such as

Europe and the United States.<sup>1</sup> The prevalence of prostate cancer has also been increasing in Japan,<sup>2</sup> concomitantly with change in life-style. Epidemiologic and genomic studies have provided a great number of information concerning exogenous factors including diet, and environmental agents, as well as endogenous factors such as genetic predisposition for susceptibility, associated with the risk of prostate cancer.<sup>3–5</sup> Dietary factors, particularly fat or well-done meat intake, are considered to strongly contribute in the genesis of prostate cancer<sup>6–8</sup> partly on the evidence that Japanese immigrants to the United States showed an increased risk of prostate cancer.<sup>9,10</sup> Our previous studies demonstrated that 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), one of the heterocyclic amines which are mutagenic compounds found in cooked meats, exerts carcinogenicity in the prostate, mammary gland and colon in rats,<sup>11,12</sup> and that spontaneously hypertensive rat (SHR) showed high susceptibility in PhIP-induced prostate carcinogenesis among the various strains of rats.<sup>13</sup> These findings prompted us to investigate the relationship between hypertension and prostate cancer development. To our knowledge, this is the first study of the effects of high blood pressure on prostate carcinogenesis in an *in vivo* animal model.

### MATERIALS AND METHODS

#### Chemicals and animals

Prazosin hydrochloride, an  $\alpha_1$ -adrenergic receptor antagonist, was purchased from Sigma (St. Louis, MO, USA). Homozygous transgenic rat for adenocarcinoma of prostate (TRAP) with a Sprague-Dawley genetic background, which were established our laboratory,<sup>14,15</sup> were bred in our animal facility. Male F344 (F344/DuCrj) rats, male SHR (SHR/NCrj) rats, and male offspring from mating of the two strains were obtained from Charles River Japan (Yokohama, Japan). Male SHR/Izm and male normotensive

Correspondence: Satoru Takahashi, MD, PhD, Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

Email: sattak@med.nagoya-cu.ac.jp

Present address: \*Department of Pathology, Luzhou Medical College, 319 ZhongShan road, Luzhou, Sichuan, China.

†School of Dental Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.

Received 14 July 2010. Accepted for publication 4 December 2010.

© 2011 The Authors

Pathology International © 2011 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd

Wistar-Kyoto (WKY) (WKY/lzm) rats were from Japan SLC Inc. (Hamamatsu, Japan). They were housed 2–3/cage on wood-chip bedding in an air-conditioned animal room at  $23 \pm 2^\circ\text{C}$  and  $50 \pm 10\%$  humidity. Food and tap water were available *ad libitum*.

### Experimental protocol

Experiment 1: Male F344 rats ( $n = 5$ ), male SHR/NCrj rats ( $n = 5$ ), male (F344  $\times$  SHR)F1 ( $n = 10$ ) and male (SHR  $\times$  F344)F1 rats ( $n = 10$ ) were killed at 10 weeks of age and their prostate glands were removed and fixed in 10% neutral formalin.

Experiment 2: Homozygous female TRAP rats were mated with male SHR/lzm or male WKY/lzm rats to generate offspring. Eighteen male (TRAP  $\times$  SHR/lzm)F1 and 18 male (TRAP  $\times$  WKY/lzm)F1 offspring were randomly divided into two groups each, and designated as groups 1–4, respectively. Rats of groups 2 and 4 continuously received 2 mg/kg/day prazosin hydrochloride in drinking water starting at 10-weeks-old for 15 weeks while groups 1 and 3 served as controls receiving tap water alone. The systolic blood pressure of all rats was measured every week by tail-cuff plethysmography (KN-210, Natsume Seisakusho, Tokyo, Japan). The experiment was terminated when the animals were 25-weeks-old. Prostate glands were removed and fixed in formalin.

The present experiments were performed under protocols approved by the Institutional Animal Care and Use


Committee of Nagoya City University Graduate School of Medical Sciences.

### Assessment of epithelial hyperplasia in the ventral prostate


We calculated the percentage area occupied by epithelial cells in acini to determine hyperplastic changes in ventral prostate. Quantitative measurement was with an Image Processor for Analytical Pathology (IPAP, Sumika Technos Co., Osaka, Japan).

### Evaluation of prostate neoplastic lesion development

Neoplastic lesions in prostate glands of TRAP rats were evaluated as previously described.<sup>16</sup> Briefly, neoplastic lesions were classified into three types, low-grade prostatic intraepithelial neoplasia (LG-PIN), high-grade PIN (HG-PIN) and adenocarcinoma, according to their structural morphologies. Low-grade PINs were characterized by having one or two layers of atypical cells with hyperchromatic nuclei and intact gland profiles. High grade PINs showed increased epithelial stratification, papillary or micropapillary proliferation of atypical epithelial cells but not filling in the acini with proliferative lesions. Adenocarcinomas were characterized by atypical cells filling almost all of the lumen of the ducts with cribriform structures or solid growth in acini (Fig. 1). The relative numbers of acini with the respective histological



**Figure 1** Representative histopathological findings for (a) low grade prostatic intraepithelial neoplasia (LG-PIN), (b) high grade PIN (HG-PIN) and (c) adenocarcinoma in lateral prostates of (spontaneously hypertensive rat (SHR)  $\times$  TRAP)F1 rats.



**Figure 2** Representative histopathological findings for ventral prostates of (a) F344, (b) spontaneously hypertensive rat (SHR), (c) (F344 × SHR)F1 and (d) (SHR × F344)F1 rats.

characteristics were quantified by counting for the total acini in each prostatic lobe.

### Immunohistochemistry

For Ki-67 immunostaining, deparaffinized sections were incubated with diluted rabbit polyclonal Ki-67 antibodies (Novocastra, Newcastle, UK). Apoptotic cells were detected using an In situ Apoptosis Detection Kit (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method) according to the manufacturer's instructions (Takara Bio Co. Ltd, Otsu, Japan). Labeling indices were counted separately in the ventral, dorsal and lateral prostate and expressed as numbers of Ki-67-positive or TUNEL-positive cells per 100 cells.

### Statistical analysis

Differences in means between groups were determined by analysis of variance (ANOVA), followed by the Dunnett's post-hoc test with GraphPad Prism (version 5.0c) (GraphPad Software, Inc., La Jolla, CA, USA).

## RESULTS

### Experiment 1

As shown in Fig. 2, both (F344 × SHR)F1 and (SHR × F344)F1 offspring developed epithelial hyperplasia of the

**Table 1** Quantitative data for epithelial content in ventral prostate of F344, SHR, and their F1 rats

Strain	No. of rats	Ventral prostate epithelium / acinus (%)
F344/DuCrj	5	28.8 ± 4.6
SHR/NCrj	5	51.4 ± 3.8
(F344 × SHR)F1	10	39.2 ± 4.7
(SHR × F344)F1	10	33.4 ± 5.9


\* $P < 0.05$ , \*\* $P < 0.001$ .

SHR, spontaneously hypertensive rat.

ventral prostate as reported previously for SHR rats.<sup>17</sup> Quantitative analysis revealed that degrees of lesion development in offspring were intermediate between those of parental F344 and SHR rats (Table 1). Values for (F344 × SHR)F1 were significantly higher than for their (SHR × F344)F1 counterparts.

### Experiment 2

Based on the results of Experiment 1, we generated hybrid rats of female TRAP rats mated with male SHR rats, or with normotensive control male WKY rats, to investigate the effect of hypertension on prostate carcinogenesis. Systolic blood pressure was sequentially monitored and the dose of prazosin was gradually increased up to 5 mg/kg/day as indicated in Fig. 3 because doses of 2 or 3 mg/kg/day proved ineffective. One rat from each of groups 2 and 4 were found dead



**Figure 3** Sequential changes of systolic blood pressure in rats given prazosin. \* $P < 0.05$  vs. G1.

**Table 2** Weights of final body, ventral prostate, and serum testosterone levels

Group	Treatment	No. of rats	Body weight (g)	Ventral prostate weight (g)	Serum testosterone (ng/mL)
1	(TRAP × SHR)F1	9	449.2 ± 17.9	0.31 ± 0.03	1.02 ± 0.28
2	(TRAP × SHR)F1 / Prazosin	8	434.9 ± 19.8	0.31 ± 0.04	2.64 ± 1.73*
3	(TRAP × WKY)F1	9	450.4 ± 18.6	0.33 ± 0.03	2.12 ± 1.18
4	(TRAP × WKY)F1 / Prazosin	8	441.9 ± 22.6	0.34 ± 0.05	1.07 ± 0.53

\* $P < 0.05$  vs. Group 1.

TRAP, transgenic rat for adenocarcinoma of prostate; SHR, spontaneously hypertensive rat; WKY, Wistar Kyoto.

during the experiment from unknown causes. The final body weights of rats given prazosin tended to be lower than those of each non-treated control but the differences were not significant. Ventral prostate weights were almost the same among the groups. Effects of prazosin or hypertensive genetic background of SHR were variable on serum testosterone levels, but the values in group 2 were significantly higher than those of group 1 (Table 2).

All rats in the present study harbored adenocarcinoma foci in their prostates regardless of their size. The numbers in the lateral prostates of hypertensive (TRAP × SHR)F1 rats demonstrated a 78% significant increase compared with those of normotensive (TRAP × WKY)F1 rats (Table 3). In the ventral prostate, increase of carcinoma foci was also apparent in (TRAP × SHR)F1 but it did not reach statistical significance. Moreover, the proportions of preneoplastic and neoplastic lesions in the lateral prostate showed that prazosin treatment tended to suppress adenocarcinoma development about 31% in (TRAP × SHR)F1 rats (Table 3). We next focused on the effect of high blood pressure on microinvasive adenocarcinoma development which is age-dependent in our TRAP rats.<sup>15</sup> In the present study, the multiplicity of invasive carcinoma foci in (TRAP × SHR)F1 rats was greater, albeit without significance, than in (TRAP × WKY)F1 rats and a tendency for decrease was found in (TRAP × SHR)F1 rats given prazosin in both of the ventral and lateral prostate (Table 4). No

differences in Ki-67 and apoptotic indices were found in any lobe among the groups (Fig. 4).

## DISCUSSION

The present experiments provided evidence that prostate cancer risk in (TRAP × SHR)F1 offspring with high blood pressure was significantly higher than that in (TRAP × WKY)F1 rats. Although the anti-hypertensive effects of prazosin were somewhat weak there appeared to be some reduction in the incidence of adenocarcinomas. Since invasive lesions are observed after 35 weeks of age in TRAP rats,<sup>15</sup> it is plausible that associations would become more apparent by extension of the experimental period.

To date, conflicting results have been published regarding possible relationships between hypertension and the risk of prostate cancer. Clear links were reported in a population-based cohort study of 82 098 men in Norway<sup>18</sup> and a case-control study of 498 African-American men in the United States.<sup>19</sup> On the other hand, data from cohort studies in Sweden with 336 159 individuals and the United States with 58 704 men demonstrated no obvious connection.<sup>20,21</sup> With data concerning anti-hypertensive drugs, use of alpha-blockers, beta-blockers or angiotensin-I-converting enzyme (ACE) inhibitors may reduce prostate cancer risk<sup>22-24</sup> although

**Table 3** Quantitative evaluation of neoplastic lesions in rat prostate

Group	Treatment	No. of rats	Relative number of acini with histological characteristics (%)									
			Ventral					Lateral				
			LG-PIN	HG-PIN	Non-invasive	Invasive	Total	LG-PIN	HG-PIN	Non-invasive	Invasive	Total
1	(TRAP × SHR)F1	9	25.6 ± 8.0	57.6 ± 8.8	16.7 ± 6.6	0.2 ± 0.3	16.9 ± 6.7	16.4 ± 5.1	69.1 ± 8.3	14.5 ± 6.3	0.2 ± 0.6	14.6 ± 6.6*
2	(TRAP × SHR)F1 / Prazosin	8	22.2 ± 5.2	62.0 ± 7.0	15.6 ± 9.1	0.2 ± 0.3	15.8 ± 9.2	20.6 ± 11.2	69.4 ± 13.3	9.8 ± 5.6	0.2 ± 0.4	10.0 ± 5.9
3	(TRAP × WKY)F1	9	26.6 ± 7.3	61.7 ± 8.0	11.6 ± 2.4	0.1 ± 0.2	11.7 ± 2.5	21.0 ± 8.7	70.7 ± 9.2	8.2 ± 5.2	0.1 ± 0.2	8.2 ± 5.0
4	(TRAP × WKY)F1 / Prazosin	8	26.8 ± 8.8	61.8 ± 10.0	11.4 ± 4.0	0	11.4 ± 4.0	14.0 ± 3.5	79.4 ± 5.2	6.5 ± 4.1	0.1 ± 0.3	6.6 ± 4.1

\**P* < 0.05 vs. Group 3.

LG-PIN, low grade prostatic intraepithelial neoplasia; HG, high grade; TRAP, transgenic rat for adenocarcinoma of prostate; SHR, spontaneously hypertensive rat; WKY, Wistar Kyoto.

prospective cohort studies provided no evidence that such medications exerted appreciable protective effects.<sup>25,26</sup>

One complicating factor might be gender and several reports have discussed the relationship between sex hormones and hypertension. Blood pressure in males is higher than in female SHR rats,<sup>27</sup> and young male SHR rats aged 9–10 weeks with chemical castration by flutamide treatment demonstrate delayed development of hypertension.<sup>28,29</sup> Moreover, administration of testosterone to ovariectomized female SHR rats exacerbates the disease.<sup>30,31</sup> There is thus mounting evidence that testosterone might play a promoting role in these animals. Intact (TRAP × SHR)F1 rats, however, showed the lowest level of serum testosterone among the groups and there was no clear association between testosterone levels and hypertension in the present study. Therefore, some factor(s) other than testosterone might be involved in the observed increased risk of prostate cancer development. A possible candidate factor is a genetic polymorphism of the angiotensin-converting enzyme (ACE) gene because this is reported to correlate with serum ACE levels,<sup>32</sup> blood pressure,<sup>33</sup> and the risk of prostate cancer in rats<sup>34–36</sup> and humans.<sup>37,38</sup> Prazosin is reported to not directly affect the renin-angiotensin system in terms of hypertension while inhibiting angiotensin II-induced DNA synthesis in vascular smooth muscle cells.<sup>39</sup> The non-significant tendency for protection observed here might not necessarily be due to lowering of blood pressure because prazosin and doxazosin *per se* have been reported to exert antitumor activity against prostate cancer cells.<sup>40,41</sup>


Spontaneously hypertensive rats are one of the most widely accepted animal models of human essential hypertension, having been characterized as closely paralleling the human disorder in its hemodynamic, endocrine, and end-organ manifestations. Systolic blood pressure in SHR is usually between 180–200 mmHg at around 5–6 weeks of age,<sup>42,43</sup> and (TRAP × SHR)F1 rats in the present study showed 170–190 mmHg. Although this level of blood pressure is much higher than patients with hypertension, it is possible to apply the current data to human patients because the control (TRAP × WKY)F1 rats exhibited 140 to 160 mmHg which is also higher than that in human cases, and the blood pressure levels in the SHR is significantly higher than that of control.

The enhancement of the prostate cancer risk in SHR rats was possibly induced due to the genetic predisposition of SHR rather than hypertension *per se*. Increased RhoA expression in vascular smooth muscle cells was constantly found in SHR compared with WKY rats<sup>44,45</sup> and RhoA activation was significantly reduced by the treatment of valsartan, an angiotensin II receptor type I blocker (ARB), but not by prazosin.<sup>44</sup> Recently, we observed a significant suppressive effect of ARBs on the prostate carcinogenesis in TRAP rats (Takahashi *et al.*, unpublished data). RhoA signaling is reported to be involved in the proliferation, migration or

**Table 4** Incidence and multiplicity of microinvasive adenocarcinoma

Group	Treatment	No. of rats	Ventral		Lateral		Anterior	
			Incidence	Multiplicity (/rat)	Incidence	Multiplicity (/rat)	Incidence	Multiplicity (/rat)
1	(TRAP × SHR)F1	9	4	0.56 ± 0.73	1	0.33 ± 1.00	8	1.11 ± 0.60
2	(TRAP × SHR)F1 / Prazosin	8	2	0.37 ± 0.74	2	0.25 ± 0.46	7	1.00 ± 0.53
3	(TRAP × WKY)F1	9	2	0.22 ± 0.44	1	0.11 ± 0.33	8	1.11 ± 0.60
4	(TRAP × WKY)F1 / Prazosin	8	0	–	2	0.25 ± 0.46	6	1.25 ± 0.89

TRAP, transgenic rat for adenocarcinoma of prostate; SHR, spontaneously hypertensive rat; WKY, Wistar Kyoto.



**Figure 4** Labeling indices for (a) Ki-67 and (b) apoptotic cells (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)) in individual prostatic lobes in Experiment 2.

metastasis of prostate cancer cells.<sup>46,47</sup> Therefore, it is speculated that RhoA restrictedly contributed to the progression from HG-PIN to adenocarcinoma but not from LG-PIN to HG-PIN in the present experimental condition because the RhoA signaling pathway is involved in relatively late-stage of prostate carcinogenesis.

In conclusion, the present animal experiment provided some evidence supporting the conclusion that development of hypertension contributes to increased prostate cancer risk.

#### ACKNOWLEDGMENTS

This work was supported by Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of

Japan and a grant from the Society for Promotion of Pathology of Nagoya, Japan.

#### REFERENCES

- 1 Coleman MP, Quaresma M, Berrino F *et al.* Cancer survival in five continents: A worldwide population-based study (CONCORD). *Lancet Oncol* 2008; **9**: 730–56.
- 2 Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. *Crit Rev Oncol Hematol* 2001; **39**: 216–26.
- 3 Bostwick DG, Burke HB, Djakiew D *et al.* Human prostate cancer risk factors. *Cancer* 2004; **101**: 2371–490.
- 4 Patel AR, Klein EA. Risk factors for prostate cancer. *Nat Clin Pract Urol* 2009; **6**: 87–95.
- 5 Witte JS. Prostate cancer genomics: Towards a new understanding. *Nat Rev Genet* 2009; **10**: 77–82.
- 6 Shirai T, Asamoto M, Takahashi S, Imaida K. Diet and prostate cancer. *Toxicology* 2002; **181–182**: 89–94.



- 7 Lophatananon A, Archer J, Easton D *et al.* Dietary fat and early-onset prostate cancer risk. *Br J Nutr* 2010; **103**: 1375–80.
- 8 Zheng W, Lee SA. Well-done meat intake, heterocyclic amine exposure, and cancer risk. *Nutr Cancer* 2009; **61**: 437–46.
- 9 Buell P, Dunn JE Jr. Cancer mortality among Japanese ISSEI and NISEI of California. *Cancer* 1965; **18**: 656–64.
- 10 Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. *Br J Cancer* 1991; **63**: 963–66.
- 11 Ito N, Hasegawa R, Sano M *et al.* A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). *Carcinogenesis* 1991; **12**: 1503–06.
- 12 Shirai T, Sano M, Tamano S *et al.* The prostate: A target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. *Cancer Res* 1997; **57**: 195–98.
- 13 Inaguma S, Takahashi S, Ohnishi H, Suzuki S, Cho YM, Shirai T. High susceptibility of the ACI and spontaneously hypertensive rat (SHR) strains to 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) prostate carcinogenesis. *Cancer Sci* 2003; **94**: 974–79.
- 14 Asamoto M, Hokaiwado N, Cho YM *et al.* Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. *Cancer Res* 2001; **61**: 4693–700.
- 15 Cho YM, Takahashi S, Asamoto M *et al.* Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats. Lack of influence of carcinogen or testosterone treatment. *Cancer Sci* 2003; **94**: 153–57.
- 16 Seeni A, Takahashi S, Takeshita K *et al.* Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. *Asian Pac J Cancer Prev* 2008; **9**: 7–14.
- 17 Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. *J Androl* 2000; **21**: 58–64.
- 18 Martin RM, Vatten L, Gunnell D, Romundstad P. Blood pressure and risk of prostate cancer: Cohort Norway (CONOR). *Cancer Causes Control* 2010; **21**: 463–72.
- 19 Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. *Cancer* 2007; **109**: 875–81.
- 20 Friedman GD. Blood pressure, and heart rate: No evidence for a positive association with prostate cancer. *Ann Epidemiol* 1997; **7**: 486–89.
- 21 Stocks T, Hergens MP, Englund A, Ye W, Stattin P. Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. *Int J Cancer* 2010; **127**: 1660–68.
- 22 Harris AM, Warner BW, Wilson JM *et al.* Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: An observational cohort study. *J Urol* 2007; **178**: 2176–80.
- 23 Lever AF, Hole DJ, Gillis CR *et al.* Do inhibitors of angiotensin I-converting enzyme protect against risk of cancer? *Lancet* 1998; **352**: 179–84.
- 24 Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and risk of prostate cancer (Canada). *Cancer Causes Control* 2004; **15**: 535–41.
- 25 Friis S, Sorensen HT, Mellenkjaer L *et al.* Angiotensin-converting enzyme inhibitors and the risk of cancer. A population-based cohort study in Denmark. *Cancer* 2001; **92**: 2462–70.
- 26 Lindholm LH, Anderson H, Ekblom T *et al.* Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: A 5-year, prospective, randomised, controlled trial. *Lancet* 2001; **358**: 539–44.
- 27 Reckelhoff JF. Gender differences in the regulation of blood pressure. *Hypertension* 2001; **37**: 1199–208.
- 28 Ganten U, Schroder G, Witt M, Zimmermann F, Ganten D, Stock G. Sexual dimorphism of blood pressure in spontaneously hypertensive rats: Effects of anti-androgen treatment. *J Hypertens* 1989; **7**: 721–26.
- 29 Reckelhoff JF, Zhang H, Srivastava K, Granger JP. Gender differences in hypertension in spontaneously hypertensive rats. Role of androgens and androgen receptor. *Hypertension* 1999; **34**: 920–23.
- 30 Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. *Hypertension* 1998; **31**: 435–39.
- 31 Reckelhoff JF, Zhang H, Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats. Role of the renin-angiotensin system. *Hypertension* 2000; **35**: 480–83.
- 32 Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 1990; **86**: 1343–46.
- 33 Sayed-Tabatabaei FA, Schut AFC, Hofman A *et al.* A study of gene-environment interaction on the gene for angiotensin converting enzyme: A combined functional and population based approach. *J Med Genet* 2004; **41**: 99–103.
- 34 Nara Y, Nabika T, Ikeda K, Sawamura M, Endo J, Yamori Y. Blood pressure cosegregates with a microsatellite of angiotensin I converting enzyme (ACE) in F2 generation from a cross between original normotensive Wistar-Kyoto rat (WKY) and stroke-prone spontaneously hypertensive rat (SHRSP). *Biochem Biophys Res Commun* 1991; **181**: 941–46.
- 35 Tremblay J, Hum DHF, Sanchez R *et al.* TA repeat variation, *Npr1* expression, and blood pressure. Impact of the *Ace* locus. *Hypertension* 2003; **41**: 16–24.
- 36 Zhang L, Summers KM, West MJ. Angiotensin I converting enzyme gene cosegregates with blood pressure and heart weight in F2 progeny derived from spontaneously hypertensive and normotensive Wistar-Kyoto rats. *Clin Exp Hypertens* 1996; **18**: 753–71.
- 37 Sierra Diaz E, Sanchez Corona J, Rosales Gomez RC *et al.* Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer. *J Renin Angiotensin Aldosterone Syst* 2009; **10**: 241–46.
- 38 Yigit B, Bozkurt N, Narter F, Yilmaz H, Yucebas E, Isbir T. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastasis. *Anticancer Res* 2007; **27**: 933–36.
- 39 van Kleef EM, Smits JFM, De Mey JGR *et al.* Alpha1-adrenoreceptor blockade reduces the angiotensin II-induced vascular smooth muscle cell DNA synthesis in the rat thoracic aorta and carotid artery. *Circ Res* 1992; **70**: 1122–27.
- 40 Garrison JB, Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. *Cancer Res* 2006; **66**: 464–72.
- 41 Lin SC, Chueh SC, Hsiao CJ *et al.* Prazosin displays anticancer activity against human prostate cancers: Targeting DNA and cell cycle. *Neoplasia* 2007; **9**: 830–39.
- 42 Trippodo NC, Frohlich ED. Similarities of genetic (spontaneous) hypertension. Man and rat. *Circ Res* 1981; **48**: 309–19.
- 43 Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: From Goldblatt to genetic engineering. *Cardiovasc Res* 1998; **39**: 77–88.

- 44 Moriki N, Ito M, Seko T *et al.* RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. *Hypertens Res* 2004; **27**: 263–70.
- 45 Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27<sup>Kip1</sup> expression in the vasculature of hypertensive rats. *Circ Res* 2001; **89**: 488–95.
- 46 Grandoch M, Rose A, ter Braak M *et al.* Epac inhibits migration and proliferation of human prostate carcinoma cells. *Br J Cancer* 2009; **101**: 2038–42.
- 47 Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, Batra SK. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-Rho A signaling pathway. *Oncogene* 2010; **29**: 1293–302.



## Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from *Momordica charantia* leaf

Pornsiri Pitchakarn<sup>a,d</sup>, Shugo Suzuki<sup>a</sup>, Kumiko Ogawa<sup>a,b</sup>, Wilart Pompimon<sup>c</sup>, Satoru Takahashi<sup>a</sup>, Makoto Asamoto<sup>a</sup>, Pornngarm Limtrakul<sup>d,\*</sup>, Tomoyuki Shirai<sup>a,\*</sup>

<sup>a</sup> Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan

<sup>b</sup> Division of Pathology, National Institute of Health Sciences, Tokyo, Japan

<sup>c</sup> Laboratory of Natural Products, Department of Chemistry, Faculty of Science, Lampang Rajabhat University, Lampang, Thailand

<sup>d</sup> Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

### ARTICLE INFO

#### Article history:

Received 18 October 2010

Received in revised form 5 February 2011

Accepted 28 February 2011

#### Keywords:

Prostate cancer

Apoptosis

Cell cycle

Bitter melon

Kuguacin J

### ABSTRACT

In this study, we focused on the effects of a bitter melon (*Momordica charantia*) leaf extract (BMLE) and a purified component, Kuguacin J (Kuj), on androgen-dependent LNCaP human prostate cancer cells. Both treatments exerted growth inhibition through G1 arrest and induction of apoptosis. In addition, Kuj markedly decreased the levels of cyclins (D1 and E), cyclin-dependent kinases (Cdk2 and Cdk4) and proliferating cell nuclear antigen, and caused an increase in p21 and p27 levels. Its induction of apoptosis was accompanied by an increase in cleavage of caspase-3 and poly (ADP-ribose) polymerase, attributable to augment of Bax/Bcl-2 and Bad/Bcl-xL and reduction of survivin levels. BMLE and Kuj also reduced the expression of androgen receptor (AR), prostate-specific antigen (PSA) while induced P53 protein level. Down-regulation of p53 by RNA interference indicated that BMLE and Kuj inhibited cell growth partly through p53-dependent cell cycle arrest and apoptotic pathways. Both BMLE and Kuj caused less toxicity in a normal prostate cell line, PNT1A. Our results suggest that BMLE and a purified component, Kuj, from its diethyl ether fraction could be promising candidate new antineoplastic and chemopreventive agents for androgen-dependent prostate cancer and carcinogenesis.

© 2011 Elsevier Ireland Ltd. All rights reserved.

### 1. Introduction

Prostate cancer is the most common male malignant tumor in Western countries [1]. The substantial associated mortality and morbidity and its limited treatment options have led to a search for novel means for prevention. Contributing risk factors include age, ethnicity, genetic factors,

and diet; in fact, diet-based agent for prevention and therapy is an attractive option based on significant findings of various epidemiologic studies, which have directly linked dietary habits to various forms of cancers, including prostate cancer [2]. Therefore, identification of bioactive compounds present in diet with potential anti-cancer efficacy has been an attractive research area in recent years [3].

Generally, deregulation of cell growth and resistance to apoptosis are major defects of cancer cells, so that approaches to induce cell cycle arrest and stimulate the apoptotic machinery could be effective. Recently, dietary phytochemicals have shown promise in this regard [4,5].

The fruit and/or leaves of *Momordica charantia*, or bitter melon, are widely consumed as a vegetable and especially as a folk medicine in Asia [6,7]. Anti-cancer activity of extracts against lymphoid leukemia, lymphoma,

\* Corresponding authors. Address: Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan, Department of Biochemistry, Faculty of Medicine, Chiangmai University, 110 Intawaroros Rd., T. Suthep, A. Maung, Chiangmai 50200, Thailand. Tel.: +81 52 853 8154; fax: +81 52 842 0817 (T. Shirai), tel.: +66 53 945325 6x218; fax: +66 53 217144/894031 (P. Limtrakul).

E-mail addresses: [plimtrak@med.cmu.ac.th](mailto:plimtrak@med.cmu.ac.th) (P. Limtrakul), [tshirai@med.nagoya-cu.ac.jp](mailto:tshirai@med.nagoya-cu.ac.jp) (T. Shirai).

choriocarcinoma, melanoma, breast cancer, skin tumor, prostatic cancer, squamous carcinoma of the tongue and larynx, human bladder carcinomas and Hodgkin's disease has been reported [6,8–12], possibly linked to antioxidant [13], antiviral (human immunodeficiency virus [HIV] inhibitor) [14], antidiabetic [15] and immunomodulating properties [16]. A previous study demonstrated that Thai *M. charantia* induced phase II enzymes and repressed monooxygenase whereas a Chinese variety only affected monooxygenase [17]. We have reported that a bitter melon leaf extract (BMLE) in Thailand increased the sensitivity to a chemotherapeutic agent, vinblastine, in cervical carcinoma KB-V1 cells [18] and inhibited invasion and migration of an androgen-independent rat prostate cancer cell line (PLS10) *in vitro* while decreasing lung metastasis *in vivo* [19]. Recently, fresh bitter melon extract demonstrated growth inhibitory effects on a breast cancer cell by modulating cell cycle regulatory genes and enhancing apoptosis [20]. Our previously study, bioguided fractionation was used to identify the active component of BMLE, which is able to modulate the function of P-glycoprotein (ABCB1) and the multidrug resistance (MDR) phenotype. We found that Kuguacin J (Kuj) inhibited P-glycoprotein-mediated MDR and increased sensitivity to vinblastine and paclitaxel in KB-V1 cells [21]. In the present study, for the first time, effects of BMLE against an androgen-dependent human prostate cancer cell line, LNCaP, *in vitro* were examined. Since BMLE is crude extract, we also focused on Kuj, a purified component.

## 2. Materials and methods

### 2.1. Plant material and extraction [21]

Bitter melon leaves were collected in Lampang province, Thailand, in March 2009. A voucher specimen (BKF No. 15602) has been deposited at the Forest Herbarium, Department of National Park, Wildlife and Plant Conservation, Ministry of Natural Resources and Environment, Bangkok, Thailand. Fresh leaves were dried at 30–45 °C, ground and powdery plant samples (1 kg) were extracted exhaustively with 4 L of 80% ethanol by maceration at 37 °C for 16 h. The mixture was filtered and re-extracted with 4 L of ethanol. The combined filtrate was bleached with 160 g of active charcoal, filtered and concentrated by rotary evaporation to 120 mL before filtering to remove precipitates. The filtrate was rotary evaporated and lyophilized twice to obtain BMLE (65.37 g) then kept at –20 °C protected from light. BMLE was dissolved in a final DMSO concentration adjusted to 0.1% (v/v) in the culture medium.

For isolation of Kuj, 100 g of BMLE was re-dissolved in 1 L of 50% methanol and successively partitioned with hexane (0.58 g), diethyl ether (13.32 g), chloroform (4.63 g), ethyl acetate (3.65 g) and an aqueous layer. Each fraction was dried under reduced pressure and then submitted to bioassays. A portion of the diethyl ether fraction (15 g) was chromatographed in a silica gel 60 (Merck KGaA, Darmstadt, Germany) column, eluting in sequence with an increasing concentration of hexane in ethyl acetate.

Further separation by silica gel 60 F254 preparative thin layer chromatography using hexane in ethyl acetate (90:10) as a mobile phase led to isolation of Kuj (1.23 g). The compound was identified as the previously described triterpenoid, Kuj, by comparison of its physical and HPLC, IR, MS and NMR data with those reported in the literature [21–25]. The purified Kuj (C<sub>30</sub>H<sub>46</sub>O<sub>3</sub>, purity >99.99% by high-resolution mass spectrometry) with a molecular weight of 454 (Fig. 2B) was dissolved in DMSO as a stock solution, and used directly in the cell culture treatments. The percentage composition of Kuj included in BMLE and the organic fraction (diethyl ether) was analyzed by HPLC.

### 2.2. Cell culture

An androgen-dependent human prostate cancer cell line, LNCaP, was purchased from The American Type Culture Collection (ATCC, Manassas, VA, USA) and a human normal prostatic epithelial cell line, PNT1A, from the Health Protection Agency Culture Collections (Salisbury, United Kingdom). The cells was cultured in Roswell Park Memorial Institute-1640 Medium (RPMI 1640, Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Life Technologies Japan Ltd., Japan), 50 U/ml penicillin and 50 µg/ml streptomycin, in a humidified incubator with an atmosphere comprising 95% air and 5% CO<sub>2</sub> at 37 °C. When the cells reached 70–80% confluence, they were harvested and plated either for subsequent passage or for treatment. DMSO was used as a vehicle control in all experiment and adjusted to the final concentration at 0.1% in culture medium. The following experiments were performed in triplicate.

### 2.3. Cytotoxicity and growth inhibition assays

LNCaP cells were plated at  $5.0 \times 10^3$  cells per well in 96-well plates. Twenty-four hours after plating, various concentrations of BMLE or Kuj were added. The cells were then incubated for 24 and 48 h at 37 °C, and cell growth were assessed by WST-1 colorimetric assay (Roche Diagnostics, Mannheim, Germany) [26].

### 2.4. Cell cycle analysis

The cells were treated with BMLE or Kuj at various concentrations for 24 or 48 h then suspensions were prepared and stained with propidium iodide (Guava<sup>®</sup> cell cycle reagent, Guava Technologies) according to the Guava<sup>®</sup> Cell Cycle Assay protocol. Cell cycle phase distributions were determined on a Guava<sup>®</sup> PCA Instrument using CytoSoft Software.

### 2.5. Apoptosis assays

Apoptosis was assessed using the Guava<sup>®</sup> Nexin reagent and the Guava<sup>®</sup> PCA system (Guava Technologies, Hayward, CA, USA). The Guava<sup>®</sup> Nexin assay utilizes two stains (annexin V and 7-amino actinomycin D [7-AAD]) to quantify the percentage of apoptotic cells. It was performed according to the manufacturer's protocol. After treatment with BMLE or Kuj for 24 or 48 h, cell suspensions were